MX2024009972A - Terapias combinadas para el tratamiento del cancer que comprenden un conjugado de farmaco anticuerpo b7-h4. - Google Patents
Terapias combinadas para el tratamiento del cancer que comprenden un conjugado de farmaco anticuerpo b7-h4.Info
- Publication number
- MX2024009972A MX2024009972A MX2024009972A MX2024009972A MX2024009972A MX 2024009972 A MX2024009972 A MX 2024009972A MX 2024009972 A MX2024009972 A MX 2024009972A MX 2024009972 A MX2024009972 A MX 2024009972A MX 2024009972 A MX2024009972 A MX 2024009972A
- Authority
- MX
- Mexico
- Prior art keywords
- drug conjugate
- cancer
- treatment
- combination therapies
- antibody drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263310967P | 2022-02-16 | 2022-02-16 | |
| US202263378295P | 2022-10-04 | 2022-10-04 | |
| PCT/EP2023/053720 WO2023156434A1 (en) | 2022-02-16 | 2023-02-15 | Combination therapies for treatment of cancer comprising b7-h4 antibody drug conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009972A true MX2024009972A (es) | 2024-08-26 |
Family
ID=85283493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009972A MX2024009972A (es) | 2022-02-16 | 2023-02-15 | Terapias combinadas para el tratamiento del cancer que comprenden un conjugado de farmaco anticuerpo b7-h4. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230310636A1 (enExample) |
| EP (1) | EP4479428A1 (enExample) |
| JP (1) | JP2025508380A (enExample) |
| KR (1) | KR20240150781A (enExample) |
| AU (1) | AU2023221516A1 (enExample) |
| CA (1) | CA3250868A1 (enExample) |
| CL (1) | CL2024002434A1 (enExample) |
| CO (1) | CO2024012148A2 (enExample) |
| CR (1) | CR20240385A (enExample) |
| IL (1) | IL314797A (enExample) |
| MX (1) | MX2024009972A (enExample) |
| TW (1) | TW202348252A (enExample) |
| WO (1) | WO2023156434A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025103407A1 (zh) * | 2023-11-16 | 2025-05-22 | 江苏豪森药业集团有限公司 | 抗体药物偶联物和多腺苷二磷酸核糖聚合酶抑制剂的联合应用 |
| TW202539742A (zh) * | 2024-02-08 | 2025-10-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗體藥物偶聯物和抗ｖｅｇｆ抗體的聯合應用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| US6828422B1 (en) | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| ATE482275T1 (de) | 1999-07-02 | 2010-10-15 | Morphosys Ag | Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
| TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
| TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
| CA2943299A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
| WO2015155345A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| TW201625689A (zh) * | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗－ｂ７－ｈ４抗體及免疫結合物 |
| US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
| WO2018195302A1 (en) * | 2017-04-19 | 2018-10-25 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| KR20240104214A (ko) | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| TWI837403B (zh) | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| CN116829592A (zh) | 2020-09-11 | 2023-09-29 | 免疫医疗有限公司 | 治疗性b7-h4结合分子 |
-
2023
- 2023-02-10 TW TW112104876A patent/TW202348252A/zh unknown
- 2023-02-15 CA CA3250868A patent/CA3250868A1/en active Pending
- 2023-02-15 MX MX2024009972A patent/MX2024009972A/es unknown
- 2023-02-15 US US18/169,497 patent/US20230310636A1/en active Pending
- 2023-02-15 JP JP2024547662A patent/JP2025508380A/ja active Pending
- 2023-02-15 IL IL314797A patent/IL314797A/en unknown
- 2023-02-15 CR CR20240385A patent/CR20240385A/es unknown
- 2023-02-15 EP EP23705984.5A patent/EP4479428A1/en active Pending
- 2023-02-15 WO PCT/EP2023/053720 patent/WO2023156434A1/en not_active Ceased
- 2023-02-15 KR KR1020247030173A patent/KR20240150781A/ko active Pending
- 2023-02-15 AU AU2023221516A patent/AU2023221516A1/en active Pending
-
2024
- 2024-08-14 CL CL2024002434A patent/CL2024002434A1/es unknown
- 2024-09-06 CO CONC2024/0012148A patent/CO2024012148A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202348252A (zh) | 2023-12-16 |
| AU2023221516A1 (en) | 2024-09-19 |
| IL314797A (en) | 2024-10-01 |
| CL2024002434A1 (es) | 2024-11-08 |
| KR20240150781A (ko) | 2024-10-16 |
| CO2024012148A2 (es) | 2024-09-30 |
| WO2023156434A1 (en) | 2023-08-24 |
| CR20240385A (es) | 2024-10-16 |
| CA3250868A1 (en) | 2023-08-24 |
| US20230310636A1 (en) | 2023-10-05 |
| JP2025508380A (ja) | 2025-03-26 |
| EP4479428A1 (en) | 2024-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015695A (es) | Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma. | |
| Yazbeck et al. | An overview of chemotoxicity and radiation toxicity in cancer therapy | |
| MX2022009044A (es) | Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina. | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| CO2024012148A2 (es) | Terapias combinadas para el tratamiento del cáncer que comprenden un conjugado de farmaco anticuerpo b7-h4 | |
| NZ576122A (en) | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| Bokobza et al. | Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| MX2024015058A (es) | Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer | |
| JOP20230243A1 (ar) | طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد | |
| MX2023013614A (es) | Uso de conjugado farmaco-anticuerpo en combinacion con inhibidor de puntos de control inmunitario en el tratamiento del cancer urotelial. | |
| Wijaya et al. | [Translated article] Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| Yu et al. | Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer | |
| ES2300323T3 (es) | Quimioterapia combinada. | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| MX2024014940A (es) | Terapia combinada para el tratamiento del cancer | |
| PH12021551951A1 (en) | Combination therapies for use in treating cancer | |
| MX2024001892A (es) | Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos. | |
| MX2023002210A (es) | Terapias combinadas con inhibidores de olig2. | |
| AR128539A1 (es) | Terapias combinadas para el tratamiento de cánceres con moléculas de unión terapéuticas | |
| MX2022013272A (es) | Conjugados de anticuerpo ccr7-farmaco para el tratamiento del cancer. |